Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the
Ultrasound contrast agent developer SonusPharmaceuticals announced this month that it has appointed TerryE. Willard as vice president of marketing and business development.Willard was formerly director of worldwide marketing in the radiopharmaceuticalsdivision of Du Pont Merck Pharmaceutical. He also held positionsat American Hospital Supply, where he developed an understandingof the injectable drug market, which will be key to marketingSonus' agents, according to the company.
Sonus, of Costa Mesa, CA, is developing intravenous ultrasoundcontrast agents based on a dodecafluoropentane-based emulsion.The company has filed an investigational new drug (IND) applicationwith the Food and Drug Administration for EchoGen, a cardiac contrastagent (SCAN 1/19/94).
European Society of Breast Imaging Issues Updated Breast Cancer Screening Recommendations
April 24th 2024One of the recommendations from the European Society of Breast Imaging (EUSOBI) is annual breast MRI exams starting at 25 years of age for women deemed to be at high risk for breast cancer.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.